This past year has seen more gene therapies approved by the FDA than the previous five years combined, and almost triple the number of clinical trials in gene therapy have been initiated in H1 of 2023 compared to the same time frame in the previous year.  To maximize the value of your late-stage gene therapy assets, the 7th Gene Therapy for Rare Disorders Summit is returning to tackle head-on the significant clinical, manufacturing, regulatory, and commercial challenges facing gene therapy programs today.

Event Link here.